Ghent University Academic Bibliography

Advanced

Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation

Gerrit S Zijlstra, Bart J Ponsioen, Sylvia A Hummel, Niek Sanders UGent, Wouter LJ Hinrichs, Anne H de Boer and Henderik W Frijlink (2009) PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY. 14(4). p.358-368
abstract
A formulation and process development study was performed to formulate recombinant human deoxyribonuclease I as a powder for inhalation. First, excipient compatibility (with bovine DNase as a model substance) was examined with a stability study at stressed conditions (60 and 85 degrees C) while monitoring for occurrence of the Maillard reaction. Next, powders for inhalation were prepared by spray drying and spray freeze drying. We found that spray drying with inulin as stabilizer resulted in the best powder for inhalation. Finally, an ex-vivo test with the spray dried rhDNase I/inulin powder significantly decreased elastic and viscous moduli of sputum from five cystic fibrosis patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PROTEIN, CYSTIC-FIBROSIS SPUTUM, RHDNASE I, AIR CLASSIFIER, ADHESIVE MIXTURES, AEROSOL DELIVERY, IGE MONOCLONAL-ANTIBODY, DE-AGGLOMERATION PRINCIPLE, HUMAN DNASE-I, SPRAY-DRIED POWDERS, Maillard reaction, rhDNase, DNase, sputum, dry powder inhalation, Protein, stabilization
journal title
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Pharm. Dev. Technol.
volume
14
issue
4
pages
358 - 368
Web of Science type
Article
Web of Science id
000269257100004
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
0.895 (2009)
JCR rank
195/236 (2009)
JCR quartile
4 (2009)
ISSN
1083-7450
DOI
10.1080/10837450802662820
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1849896
handle
http://hdl.handle.net/1854/LU-1849896
date created
2011-06-30 15:41:30
date last changed
2011-07-01 14:31:25
@article{1849896,
  abstract     = {A formulation and process development study was performed to formulate recombinant human deoxyribonuclease I as a powder for inhalation. First, excipient compatibility (with bovine DNase as a model substance) was examined with a stability study at stressed conditions (60 and 85 degrees C) while monitoring for occurrence of the Maillard reaction. Next, powders for inhalation were prepared by spray drying and spray freeze drying. We found that spray drying with inulin as stabilizer resulted in the best powder for inhalation. Finally, an ex-vivo test with the spray dried rhDNase I/inulin powder significantly decreased elastic and viscous moduli of sputum from five cystic fibrosis patients.},
  author       = {Zijlstra, Gerrit S and Ponsioen, Bart J and Hummel, Sylvia A and Sanders, Niek and Hinrichs, Wouter LJ and de Boer, Anne H and Frijlink, Henderik W},
  issn         = {1083-7450},
  journal      = {PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY},
  keyword      = {PROTEIN,CYSTIC-FIBROSIS SPUTUM,RHDNASE I,AIR CLASSIFIER,ADHESIVE MIXTURES,AEROSOL DELIVERY,IGE MONOCLONAL-ANTIBODY,DE-AGGLOMERATION PRINCIPLE,HUMAN DNASE-I,SPRAY-DRIED POWDERS,Maillard reaction,rhDNase,DNase,sputum,dry powder inhalation,Protein,stabilization},
  language     = {eng},
  number       = {4},
  pages        = {358--368},
  title        = {Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation},
  url          = {http://dx.doi.org/10.1080/10837450802662820},
  volume       = {14},
  year         = {2009},
}

Chicago
Zijlstra, Gerrit S, Bart J Ponsioen, Sylvia A Hummel, Niek Sanders, Wouter LJ Hinrichs, Anne H de Boer, and Henderik W Frijlink. 2009. “Formulation and Process Development of (recombinant Human) Deoxyribonuclease I as a Powder for Inhalation.” Pharmaceutical Development and Technology 14 (4): 358–368.
APA
Zijlstra, G. S., Ponsioen, B. J., Hummel, S. A., Sanders, N., Hinrichs, W. L., de Boer, A. H., & Frijlink, H. W. (2009). Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 14(4), 358–368.
Vancouver
1.
Zijlstra GS, Ponsioen BJ, Hummel SA, Sanders N, Hinrichs WL, de Boer AH, et al. Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY. 2009;14(4):358–68.
MLA
Zijlstra, Gerrit S, Bart J Ponsioen, Sylvia A Hummel, et al. “Formulation and Process Development of (recombinant Human) Deoxyribonuclease I as a Powder for Inhalation.” PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY 14.4 (2009): 358–368. Print.